Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study<sup>*</sup>

ZHANG Wen; WU Hong-ze; XU Xiang-ru; PU Yu-ting; CHEN Cai-yu; DENG Rou; CAO Min; SUN Ding; YI Hui; ZHOU Shuang; FANG Bang-jiang

doi:10.1007/s11655-024-3921-3

Your Location：

Home >

Browse articles >

Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*

Original Article | Updated：2025-04-22

- Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*
- Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*
- 中国结合医学杂志（英文版） 2025年31卷第5期页码：387-393
- Affiliations：
  
  1.Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai (200032), China
  2.Institute of Emergency and Critical Care Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai (200032), China
  3.Department of Spleen and Stomach Diseases, Jiujiang Traditional Chinese Medicine Hospital, Jiujiang, Jiangxi Province (332005), China
  4.Department of Rheumatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai (200032), China
  5.School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai (201203), China
- Author bio：
  
  Prof. FANG Bang-jiang, E-mail: fangbji@163.com
- Funds：
  
  Traditional Chinese Medicine Emergency Project on Novel Coronavirus-Infected Pneumonia of State Administration of Traditional Chinese Medicine(2022ZYLCYJ05-4);Shanghai University of Traditional Chinese Medicine, Traditional Chinese Medicine on Prevention and Treatment of Novel Coronavirus Pneumonia Emergency and Special Project(2022YJ-03;2022YJ-06)
- DOI：10.1007/s11655-024-3921-3
  中图分类号：
- 录用日期：2023-06-25，
  
  网络出版日期：2025-01-25，
  
  纸质出版日期：2025-05
- Accepted：
Scan QR Code
Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*[J]. 中国结合医学杂志（英文版）, 2025,31(5):387-393.

ZHANG Wen, WU Hong-ze, XU Xiang-ru, et al. Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*[J]. Chinese journal of integrative medicine, 2025, 31(5): 387-393.
Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*[J]. 中国结合医学杂志（英文版）, 2025,31(5):387-393. DOI： 10.1007/s11655-024-3921-3.

ZHANG Wen, WU Hong-ze, XU Xiang-ru, et al. Effect and Safety of Fuzheng Huazhuo Decoction against Prolonged SARS-CoV-2 Clearance: A Retrospective Cohort Study^*[J]. Chinese journal of integrative medicine, 2025, 31(5): 387-393. DOI： 10.1007/s11655-024-3921-3.

摘要

Abstract

Objective:

To evaluate the effect and safety of Chinese medicine (CM) Fuzheng Huazhuo Decoction (FHD) in treating patients with coronavirus disease 2019 (COVID-19) who persistently tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods:

This retrospective cohort study was conducted at Shanghai New International Expo Center shelter hospital in China between April 1 and May 30

2022. Patients diagnosed as COVID-19 with persistently positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test results for 8 days after diagnosis were enrolled. Patients in the control group received conventional Western medicine (WM) treatment

while those in the FHD group received conventional WM plus FHD for at least 3 days. The primary outcome was viral clearance time. Secondary outcomes included negative conversion rate within 14 days

length of hospital stay

cycle threshold (Ct) values of the open reading frame 1ab (ORF1ab) and nucleocapsid protein (N) genes

and incidence of new-onset symptoms during hospitalization. Adverse events (AEs) that occurred during the study period were recorded.

Results:

A total of 1

765 eligible patients were enrolled in this study (546 in the FHD group and 1

219 in the control group). Compared with the control group

patients receiving FHD treatment showed shorter viral clearance time for nucleic acids [hazard ratio (HR): 1.500

95% conf

idence interval (CI): 1.353–1.664

0.001

]

and hospital stays (HR: 1.371

95% CI: 1.238–1.519

0.001)

and a higher negative conversion rate within 14 days (96.2%

. 82.6%

0.001). The incidence of new-onset symptoms was 59.5% in the FHD group

similar to 57.8% in the control group (

0.05). The Ct values of ORF1ab and N genes increased more rapidly over time in the FHD group than those in the control group post-randomization (ORF1ab gene:

=0.436±0.053

0.001; N gene:

=0.415±0.053

0.001). The incidence of AEs in the FHD group was lower than that in the control group (24.2%

. 35.4%

0.001). No serious AEs were observed.

Conclusion:

FHD was effective and safe for patients with persistently positive SARS-CoV-2 PCR tests. (Registration No. ChiCTR2200063956)

关键词

Keywords

references

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Severe Type of COVID-19: Pathogenesis,Warning Indicators and Treatment

Clinical Practice Guidelines and Experts' Consensuses for Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Chinese Herbal Medicine: A Systematic Review

Mechanism of Reactive Oxygen/Nitrogen Species in Liver Ischemia-Reperfusion Injury and Preventive Effect of Chinese Medicine^*

Mechanism of Astragaloside Ⅳ in Treatment of Renal Tubulointerstitial Fibrosis^*

Efficacy and Safety of Chinese Medicine Resuscitation Pack for Enhanced Recovery after Bronchoscopy: A Randomized, Single-Blind, Placebo-Controlled Clinical Trial^*